San Francisco-based Benchling, provider of a data management and collaboration platform for life sciences research, announced it has raised a $14.5 million Series B round of funding. Benchmark led the financing and General Partner Eric Vishria will join the company board. Also joining the round are F-Prime Capital, which is a firm associated with Fidelity Investments, and returning investor Thrive Capital. The company has now raised more than $27 million since it was founded in 2012.
Benchling customers include Regeneron Pharmaceuticals, Incyte, Editas Medicine, Agenus, Zymergen and Obsidian Therapeutics.
“We started Benchling to help scientists make better decisions faster and use their time on higher-impact work such as experimental strategy and design,” said Benchling co-founder and CEO Sajith Wickramasekara in a prepared release. “Our hope is that they can advance life sciences at a faster pace and do in 10 years what otherwise may take 30 to 50.”
Source: Company blog post